Latest news
HRTX: Q2 net revenue grew to $37.7M, but guidance was withdrawn due to CINVANTI patent uncertainty - TradingViewTradingView · Mon, 10 Aug 2026 13:32:09 GMTHRTX: Acute care sales surged, oncology declined, and net loss widened amid ongoing strategic review - TradingViewTradingView · Mon, 10 Aug 2026 12:16:13 GMTHeron Therapeutics reports Q2 2026 revenue $37.7M, withdraws 2026 guidance after patent ruling - TradingViewTradingView · Mon, 10 Aug 2026 12:03:01 GMTHeron Therapeutics Inc expected to post earnings of 1 cent a share - Earnings Preview - TradingViewTradingView · Fri, 07 Aug 2026 17:00:07 GMTHRTX Q2'26 Earnings: EPS estimate is (0.01) USD - TradingViewTradingView · Fri, 07 Aug 2026 11:00:26 GMTHeron Therapeutics, Inc. Revenue Breakdown – NASDAQ:HRTX - TradingViewTradingView · Sat, 01 Aug 2026 05:02:16 GMT